Home > Insider Trading > Filing (0000899243-21-002081)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1789972	Cullinan Management Inc.	CGEM	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687078	Mpm Oncology Impact Management Lp	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	Ubs Trustees (Cayman) Ltd 5Th Fl Cayman Corp Center 27 Hospital George Town E9 KY1-1106	No	No	Yes	No
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	Ubs Trustees (Cayman) Ltd 5Th Fl Cayman Corp Center 27 Hospital George Town E9 KY1-1106	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-12	1,136,525	$0.00	1,136,525	No	4	C	Direct
Common Stock	Acquisiton	2021-01-12	3,551,640	$0.00	4,688,165	No	4	C	Direct
Common Stock	Acquisiton	2021-01-12	2,276,692	$0.00	6,964,857	No	4	C	Direct
Common Stock	Acquisiton	2021-01-12	649,030	$0.00	7,613,887	No	4	C	Direct
Common Stock	Acquisiton	2021-01-12	300,000	$21.00	7,913,887	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Convertible Preferred Stock	Disposition	2021-01-12	1,136,525	$0.00	1,136,525	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2021-01-12	3,551,640	$0.00	3,551,640	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-01-12	2,276,692	$0.00	2,276,692	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-01-12	649,030	$0.00	649,030	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.
Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering.